A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

NCT07189949

Status	RECRUITING
Phase	Phase 1
Sponsor	Jiangsu HengRui Medicine Co., Ltd.
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (7)

- Have fully understood this study and are willing to sign the ICF, with good compliance and cooperation in follow-up;
- Aged between 18-75 years old;
- Participants with histologically/cytologically confirmed advanced solid tumors who have been previously tested or are confirmed by the central laboratory to harbor RAS mutations or amplifications and have failed standard treatment;
- ECOG performance status (PS) score of 0 or 1;
- Life expectancy \> 3 months;

... and 2 more (see full listing online)

Exclusion (11)

- Presence of central nervous system (CNS) metastases;
- Participants with gastrointestinal diseases that affect drug administration/absorption;
- Participants who have undergone major surgery other than diagnosis or biopsy within 28 days before the first dose, or are expected to undergo major surgery during the study period;
- Presence of serious pulmonary diseases;
- Active tuberculosis or a history of active tuberculosis infection within 48 weeks prior to screening, regardless of whether they have been treated;

... and 6 more (see full listing online)

Locations (1 total)

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality, China